Cory David A 4
4 · Eiger BioPharmaceuticals, Inc. · Filed Mar 26, 2019
Insider Transaction Report
Form 4
Cory David A
DirectorPresident and CEO
Transactions
- Award
Stock Option ( Right to Buy)
2019-03-21+200,000→ 200,000 totalExercise: $14.31Exp: 2029-03-20→ Common Stock (200,000 underlying) - Award
Common Stock
2018-09-05$7.95/sh+1,500$11,921→ 64,503 total - Award
Common Stock
2017-03-06$8.20/sh+1,325$10,868→ 60,003 total - Award
Common Stock
2017-09-05$9.90/sh+1,500$14,854→ 61,503 total - Award
Common Stock
2018-03-05$8.03/sh+1,500$12,049→ 63,003 total - Award
Common Stock
2019-03-05$7.95/sh+1,500$11,921→ 66,003 total
Holdings
- 30,123(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]Includes shares acquired under the Issuer's Employee Stock Purchase Plan in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]Represents the Reporting Person's proportionate interest in securities held by Eiccose, LLC ("Eiccose"). The Reporting Person is a managing member and significant equity interest holder of Eiccose. The Reporting Person hereby disclaims any beneficial ownership of any shares directly held by Eiccose, except to the extent of its pecuniary interest therein.
- [F3]The option vests in equal monthly installments over 48 months measured from March 21, 2019 subject to Reporting Person's continuous service status as of each such date.